# SCG Cell Therapy Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scg-cell-therapy-pte

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.scgcell.com
- Total disclosed funding: $18M
- Latest round: Series C (Jun 11, 2021)
- Investors on record: 2

## About

Based in Singapore, and founded in 2017 by its scientific founder Prof. Dr. Ulrike Protzer, SCG Cell Therapy Pte Ltd. operates as a biotechnology company that harnesses the patient's immune system to target pathogenic infections or related antigens to prevent and treat cancer. As of June 2022, the company is led by its CEO Frank Wang and has a scientific network in Singapore, China, and Germany.

SCG Cell Therapy Pte Ltd. develops T cell therapies, bispecific antibodies, and therapeutic vaccines for common cancer-causing infections: hepatitis B, helicobacter pylori, and human papillomavirus and associated malignancies. It creates an immunotherapy pipeline for pathogen-associated solid tumors combining multiple platforms and proprietary insights to deliver solutions for patients.

## Funding rounds

- Series C, Jun 11, 2021, $18M — V Star Capital, Smartech

## Investors

- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Series C
- Smartech — Series C